Nurix Reports Positive Results of BTK degraders, NX-5948 and NX-2127 in P-Ia/Ib Trial for the Treatment of Lymphoma
Shots:
- Nurix Therapeutics reveals positive clinical results for its BTK degraders, NX-5948 and NX-2127 in separate P-1a/1b trials for r/r B-cell malignancies. The results of the NX-5948 P-Ia/Ib study depicted dose-dependent PK in cohorts 1-5, (n=26; 50-450 mg) with 4 prior therapies
- Additionally, CLL patients (50-200 mg) exhibited clinical benefit in 6/7, with ongoing responses; NHL patients (50-450 mg) showed durable responses, & it was well-tolerated across all doses (50-450 mg), with no toxicities or discontinuations by Oct 17, 2023
- Furthermore, Nurix's NX-2127 trial (Phase Ia/Ib, CLL, MCL, DLBCL) on patients (n=56; aged:50-92; 100-300 mg) showed dose-dependent PK, induced rapid & durable responses, with complete responses in 2/17 NHL patients. In CLL patients, an ORR of 40.7% was observed
Ref: Nurix | Image: Nurix
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
